DGAP-News: Fresenius Medical Care AG & Co. KGaA reports second quarter 2015 results and confirms guidance for full year 2015

Fresenius Medical Care AG & Co. KGaA reports second quarter 2015 results and confirms guidance for full year 2015

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Schlagwort(e):

Halbjahresergebnis

Fresenius Medical Care AG & Co. KGaA reports second quarter 2015

results and confirms guidance for full year 2015

29.07.2015 / 22:53

---------------------------------------------------------------------

July 29, 2015

INVESTOR

NEWS

Fresenius Medical Care reports

second quarter 2015 results and confirms guidance for full year 2015

- Second quarter performance on track to achieve full year guidance for

2015

- Strong year to date revenue and earnings growth

- International performance mainly masked by currencies in the second

quarter

- Strong year to date cash flow generation

Second quarter 2015 key figures:

Net revenue $4,199 million +9%

Operating income (EBIT) $547 million -2%

Net income1 $241 million +3%

Basic earnings per share $0.79 +2%

First half 2015 key figures:

Net revenue $8,159 million +10%

Operating income (EBIT) $1,051 million +5%

Net income1 $450 million +3%

Basic earnings per share $1.48 +2%

Rice Powell, chief executive officer of Fresenius Medical Care stated: "Our

second quarter 2015 results showed a positive underlying performance. We

are pleased with our revenue and earnings growth considering the negative

currency impact on our International operations in the second quarter. We

have made further progress with the integration of our Care Coordination

operations. Our performance is in line with our full year guidance for 2015

and we are confident to achieve our long-term targets for 2020."

Second quarter 2015

Revenue

Net revenue for the second quarter of 2015 increased by 9% to $4,199

million (+15% at constant currency) as compared to the second quarter of

2014. Organic revenue growth worldwide was 8%. Net Health Care revenue grew

by 13% to $3,345 million (+18% at constant currency).

_________________________

1 attributable to shareholders of Fresenius Medical Care AG&Co. KGaA

The dialysis product revenue decreased by 4% to $854 million as compared to

the second quarter of 2014 mainly due to negative currency developments in

the International product business. On a constant currency basis the

dialysis product revenue increased by 8%.

North America revenue for the second quarter of 2015 increased by 17% to

$2,946 million. Organic revenue growth was 7%. Net Health Care revenue grew

by 17% to $2,722 million with a same market treatment growth of 4%. Net

Dialysis Care revenue increased by 6% to $2,254 million while the Care

Coordination revenue increased by 149% to $468 million (organic growth of

24%). Dialysis product revenue increased by 9% to $224 million as compared

to the second quarter of 2014.

International revenue decreased by 4% to $1,247 million. On a constant

currency basis revenue increased by 14%. Organic revenue growth was 9%. Net

Health Care revenue decreased by 1% to $623 million (+18% at constant

currency). Dialysis product revenue decreased by 6% to $624 million (+10%

at constant currency).

International segments:

Europe, Middle East and Africa (EMEA) revenue decreased by 15% to $668

million (+4% at constant currency). Organic revenue growth was 5%. Net

Health Care revenue decreased by 17% to $309 million (+3% at constant

currency). Dialysis product revenue decreased by 14% to $359 million (+5%

at constant currency).

Asia-Pacific revenue increased by 22% to $376 million (+32% at constant

currency). Organic revenue growth was 12%. Net Health Care revenue

increased by 37% to $164 million (+55% at constant currency). Dialysis

product revenue increased by 12% to $212 million (+18% at constant

currency).

Latin America revenue increased by 2% to $203 million (+22% at constant

currency). Organic revenue growth was 19%. Net Health Care revenue

increased by 6% to $150 million (+25% at constant currency). Dialysis

product revenue decreased by 8% to $53 million (+15% at constant currency).

Earnings

Operating income (EBIT) decreased by 2% from $556 million in the second

quarter of 2014 to $547 million in the second quarter of 2015.

Operating income for North America for the second quarter of 2015 was $428

million, an increase of 7% as compared to the second quarter of 2014.

In the International segments, operating income for the second quarter of

2015 decreased by 11% to $217 million as compared to $243 million in the

second quarter of 2014.

International segments: Operating income for EMEA for the second quarter of

2015 was $134 million, a decrease of 20% as compared to the second quarter

of 2014. Operating income for Asia-Pacific for the second quarter of 2015

was $67 million, an increase of 22% as compared to the second quarter of

2014. Operating income for Latin America for the second quarter of 2015 was

$16 million, a decrease of 20% as compared to the second quarter of 2014.

Net interest expense for the second quarter of 2015 was $102 million as

compared to $98 million in the second quarter of 2014 which mainly reflects

the financing costs of the acquisitions made in the second half of 2014.

Income tax expense was $135 million for the second quarter of 2015, which

translates into an effective tax rate of 30.4%. On an adjusted basis the

tax rate for the second quarter of 2014 was 34.8%².

Net income attributable to shareholders of Fresenius Medical Care AG & Co.

KGaA for the second quarter of 2015 was $241 million, an increase of 3%

compared to $234 million for the second quarter of 2014 and in line with

our full year guidance for 2015.

Basic earnings per share (EPS) for the second quarter of 2015 was $0.79, an

increase of 2% compared to the corresponding number for the second quarter

of 2014. The weighted average number of shares outstanding for the second

quarter of 2015 was approximately 304.2 million shares, compared to

approximately 301.8 million shares for the second quarter of 2014. The

increase in shares outstanding resulted from stock option exercises during

the second quarter of 2015.

_________________________

² The tax rate in the second quarter of 2014 was influenced by a special

tax impact which resulted in an expense of $18 million.

Cash flow

In the second quarter of 2015, the company generated $385 million,

representing 9.2% of revenue, in net cash provided by operating activities,

compared to the corresponding figure of last year of $449 million.

A total of $214 million was spent for capital expenditures, net of

disposals. Free cash flow was $171 million compared to $231 million in the

second quarter of 2014.

A total of $55 million in cash was spent for acquisitions, net of

divestitures. Free cash flow after investing activities was $116 million as

compared to ($66) million in the second quarter of 2014.

First half 2015

Revenue and earnings

Net revenue for the first half of 2015 increased by 10% to $8,159 million

(+16% at constant currency) as compared to the first half of 2014. Organic

revenue growth worldwide was 8%.

Operating income (EBIT) for the first half of 2015 was $1,051 million as

compared to $1,001 million in the first half of 2014. This represents an

increase of 5% on a reported basis.

Net interest expense for the first half of 2015 was $204 million as

compared to $195 million in the first half of 2014.

Income tax expense for the first half of 2015 was $273 million, which

translates into an effective tax rate of 32.2%. On an adjusted basis the

tax rate for the first half of 2014 was 32.3%.² For the full year, the

company expects the tax rate to be on the lower end of its guidance range

of 33 to 34%.

_________________________

² The tax rate in the second quarter of 2014 was influenced by a special

tax impact which resulted in an expense of $18 million.

For the first half of 2015, net income attributable to shareholders of

Fresenius Medical Care AG & Co. KGaA was $450 million, up by 3% from the

corresponding number of $439 million for the first half of 2014.

In the first half of 2015, basic earnings per share (EPS) was $1.48, an

increase of 2% compared to the corresponding number for the first half of

2014. The weighted average number of shares outstanding during the first

half of 2015 was approximately 303.9 million shares.

Cash flow

In the first half of 2015, the company generated $832 million in net cash

provided by operating activities, representing 10.2% of revenue, as

compared to $562 million for the same period in 2014.

A total of $411 million was spent for capital expenditures, net of

disposals. Free cash flow for the first half of 2015 was $421 million as

compared to $147 million in the first half of 2014.

A total of $66 million in cash was spent for acquisitions and investments,

net of divestitures. Free cash flow after investing activities was $355

million as compared to a ($285) million in the first half of 2014.

Employees

As of June 30, 2015, Fresenius Medical Care had 102,893 employees

(full-time equivalents) worldwide, compared to 94,401 employees at the end

of June 2014. This increase of ~8,500 employees was mainly attributable to

acquisitions as well as our continued organic growth.

Balance sheet structure

The company's total assets of $25,410 million remained on a similar level

(Dec. 31, 2014: $25,447 million). Current assets were virtually flat at

$6,702 million (Dec. 31, 2014: $6,725 million). Non-current assets remained

almost unchanged at $18,708 million (Dec. 31, 2014: $18,722 million). Total

equity increased by 2% to $10,182 million (Dec. 31, 2014: $10,028 million).

The equity ratio was 40% as compared to 39% at the end of 2014. Total debt

was $9,270 million (Dec. 31, 2014: $9,532 million). As of June 30, 2015,

the debt/EBITDA ratio was 3.0 (Dec. 31, 2014: 3.1).

Please refer to the attachments for a complete overview of the results for

the second quarter and first half of 2015 and the reconciliation of

non-GAAP financial measures included in this release to the most comparable

GAAP financial measures.

Outlook³ confirmed

For the 2015 outlook the company expects revenue to grow at 5-7%, which at

constant currency is a growth rate of 10-12%. Net income attributable to

shareholders of Fresenius Medical Care AG & Co. KGaA is expected to

increase by 0-5% in 2015.

The company expects to spend around $1.0 billion on capital expenditures

and around $400 million on acquisitions in 2015. The debt/EBITDA ratio is

expected to be around 3.0 by the end of 2015.

For the 2016 projections we expect revenue to increase around 7-10%

(previously 9-12%). This is due to the fact that we expect some of the

initiatives in Care Coordination operations to be delayed into the

following years. The net income attributable to shareholders of Fresenius

Medical Care AG & Co. KGaA is still expected to grow by 15-20% (unchanged).

As disclosed in the company's long-term target for 2020, the company

expects revenue to grow at an average annual growth rate of approx. 10% and

net income attributable to shareholders in the high single digits.

_________________________

³ The outlook/projection provided for 2015/2016 is based on current

exchange rates. Savings from the global efficiency program are included,

while potential acquisitions are not. In addition the outlook reflects

further operating cost investments within the Care Coordination business

for future growth in line with our 2020 strategy.

Conference call

Fresenius Medical Care will hold a conference call to discuss the results

of the second quarter 2015 on Thursday, July 30, 2015 at 3.30 p.m. CEDT/

9.30 a.m. EDT. The company invites investors to follow the live webcast of

the call at the company's website www.freseniusmedicalcare.com in the

"Investors/Events" section. A replay will be available shortly after the

call.

Fresenius Medical Care is the world's largest provider of products and

services for individuals with renal diseases of which more than 2.6 million

patients worldwide regularly undergo dialysis treatment. Through its

network of 3,421 dialysis clinics, Fresenius Medical Care provides dialysis

treatments for 289,610 patients around the globe. Fresenius Medical Care is

also the leading provider of dialysis products such as dialysis machines or

dialyzers. Along with the core business, the company focuses on expanding

the range of additional medical services in the field of care coordination.

For more information about Fresenius Medical Care, visit the company's

website at www.freseniusmedicalcare.com.

Disclaimer

This release contains forward-looking statements that are subject to

various risks and uncertainties. Actual results could differ materially

from those described in these forward-looking statements due to certain

factors, including changes in business, economic and competitive

conditions, regulatory reforms, foreign exchange rate fluctuations,

uncertainties in litigation or investigative proceedings, and the

availability of financing. These and other risks and uncertainties are

detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the

U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.

KGaA does not undertake any responsibility to update the forward-looking

statements in this release.

---------------------------------------------------------------------

29.07.2015 Veröffentlichung einer Corporate News/Finanznachricht,

übermittelt durch DGAP - ein Service der EQS Group AG.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber

verantwortlich.

Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,

Corporate News/Finanznachrichten und Pressemitteilungen.

Medienarchiv unter http://www.dgap-medientreff.de und

http://www.dgap.de

---------------------------------------------------------------------

Sprache: Deutsch

Unternehmen: Fresenius Medical Care AG & Co. KGaA

Else-Kröner-Straße 1

61352 Bad Homburg

Deutschland

Telefon: +49 (0) 6172- 609 2525

Fax: +49 (0) 6172- 609 2301

E-Mail: ir@fmc-ag.com

Internet: www.fmc-ag.de

ISIN: DE0005785802, DE0005785836,

WKN: 578580, 578583

Indizes: DAX

Börsen: Regulierter Markt in Frankfurt (Prime Standard);

Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,

München, Stuttgart; Terminbörse EUREX; NYSE

Ende der Mitteilung DGAP News-Service

---------------------------------------------------------------------

382119 29.07.2015